研究者業績

佐田 尚宏

サタ ナオヒロ  (Naohiro Sata)

基本情報

所属
自治医科大学 医学部外科学講座 消化器一般移植外科学部門 主任教授 (附属病院 病院長)
(兼任)病院長
学位
医学博士(東京大学)

J-GLOBAL ID
200901010372664634
researchmap会員ID
1000300013

学歴

 2

論文

 663
  • Daigo Kuboki, Teruhiko Unoki, Yuji Kaneda, Yoshitaka Maeda, Kosuke Oiwa, Hironori Yamaguchi, Naohiro Sata, Hiroshi Kawahira
    Surgery Open Science 2025年2月  
  • Takahiko Omameuda, Yukihiro Sanada, Yasunaru Sakuma, Yasuharu Onishi, Taiichi Wakiya, Yuta Hirata, Toshio Horiuchi, Kiichiro Takadera, Ryosuke Akimoto, Naohiro Sata
    Clinical journal of gastroenterology 17(6) 1080-1086 2024年12月  
    Portal cavernoma cholangiopathy (PCC) is a complex condition associated with portal hypertension, particularly in patients with extrahepatic portal vein obstruction (EHPVO). Herein, we present a case of liver failure with PCC in a 55-year-old male successfully treated with living-donor liver transplantation (LDLT). The patient had a history of gastrointestinal bleeding and recurrence of cholangitis. Imaging studies confirmed cavernous transformation and pericholedochal varices. Preoperative angiography verified hepatopetal flow in the pericholedochal varix, which facilitated successful anastomosis with the donor's portal vein during LDLT. Histological examination of the explanted liver confirmed vanishing bile duct syndrome (VBDS) and secondary bile stasis was considered to have caused liver failure. No postoperative complications were observed within 13 months of LDLT. We report the first case of VBDS in the PCC resulting from EHPVO that was successfully managed with LDLT. Careful management of similar cases should involve angiography and long-term postoperative monitoring of portal vein complications.
  • Naoya Kasahara, Takumi Teratani, Junshi Doi, Shinichiro Yokota, Kentaro Shimodaira, Yuki Kaneko, Hideyuki Ohzawa, Yasunaru Sakuma, Hideki Sasanuma, Yasuhiro Fujimoto, Taizen Urahashi, Hideyuki Yoshitomi, Hironori Yamaguchi, Joji Kitayama, Naohiro Sata
    Stem cell research & therapy 15(1) 395-395 2024年11月4日  
    BACKGROUND: Globally, prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing, and there is an urgent need to develop innovative therapies that promote liver regeneration following hepatectomy for this disease. Surgical excision is a key therapeutic approach with curative potential for liver tumors. However, hepatic steatosis can lead to delayed liver regeneration and higher post-operative complication risk. Mesenchymal stem cells-conditioned medium (MSC-CM) is considered a rich source of paracrine factors that can repair tissues and restore function of damaged organs. Meanwhile, hydrogels have been widely recognized to load MSC secretome and achieve sustained release. This study aimed to evaluate the therapeutic effect of hydrogel-encapsulated MSC-CM on liver regeneration following partial hepatectomy (PHx) in a rodent model of diet-induced hepatic steatosis. METHODS: Male Lewis rats were fed with a methionine and choline-deficient diet. After 3 weeks of feeding, PHx was performed and rats were randomly allocated into two groups that received hydrogel-encapsulated MSC-CM or vehicle via the intra-mesenteric space of the superior mesenteric vein (SMV). RESULTS: The regeneration of the remnant liver at 30 and 168 h after PHx was significantly accelerated, and the expressions of proliferating cell nuclear antigen were significantly enhanced in the MSC-CM group. MSC-CM treatment significantly increased hepatic ATP and β-hydroxybutyrate content at 168 h after PHx, indicating that MSC-CM fosters regeneration not only in volume but also in functionality. The number of each TUNEL- and cleaved caspase-3 positive nuclei in hepatocytes at 9 h after PHx were significantly decreased in the MSC-CM group, suggesting that MSC-CM suppressed apoptosis. MSC-CM increased serum immunoregulatory cytokine interleukin-10 and interleukin-13 at 30 h after PHx. Additionally, mitotic figures and cyclin D1 expression decreased and hepatocyte size increased in the MSC-CM group, implying that this mode of regeneration was mainly through cell hypertrophy rather than cell division. CONCLUSIONS: MSC-CM represents a novel therapeutic approach for patients with MASLD requiring PHx.
  • Yusuke Sakurai, Kensuke Yokoyama, Atsushi Kanno, Akitsugu Tanaka, Eriko Ikeda, Kozue Ando, Masanobu Taguchi, Hideki Sasanuma, Naohiro Sata, Naoki Sano, Noriyoshi Fukushima, Hironori Yamamoto
    Internal medicine (Tokyo, Japan) 2024年10月25日  
    A 50-year-old man was diagnosed with type 1 autoimmune pancreatitis (AIP) following endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) and a histopathological examination. After six months of untreated follow-up, the serum IgG4 level decreased, and the diffuse pancreatic enlargement improved; however, a pancreatic head mass became apparent. EUS-FNA of this mass revealed pancreatic ductal adenocarcinoma (PDAC) with IgG4-positive plasma cells. In addition, the resected specimen revealed PDAC, without any features of AIP. After pancreatoduodenectomy, AIP did not recur. The development of AIP in this case could be related to paraneoplastic syndrome.
  • Yuki Kaneko, Hideyuki Ohzawa, Yuki Kimura, Rei Takahashi, Misaki Matsumiya, Kohei Tamura, Yurie Futoh, Hideyo Miyato, Shin Saito, Hironori Yamaguchi, Yoshinori Hosoya, Ryota Watano, Hiroaki Mizukami, Naohiro Sata, Joji Kitayama
    Cancer gene therapy 2024年10月10日  
    This study explores a novel therapeutic approach for peritoneal metastasis (PM) using AAV-mediated delivery of tumor suppressor microRNA-29b (miR-29b) to peritoneal mesothelial cells (PMC). AAV serotypes 2 and DJ demonstrate high transduction efficiency for human and murine PMC, respectively. In vitro analysis indicates that AAV vectors encoding miR-29b precursor successfully elevate miR-29b expression in PMC and their secreted small extracellular vesicle (sEV), thereby inhibiting mesothelial mesenchymal transition and reducing subsequent attachment of tumor cells. A single intraperitoneal (IP) administration of AAV-DJ-miR-29b demonstrates robust and sustained transgene expression, suppressing peritoneal fibrosis and inhibiting the development of PM from gastric and pancreatic cancers. Additionally, AAV-DJ-miR-29b enhances the efficacy of IP chemotherapy using paclitaxel, restraining the growth of established PM. While conventional gene therapy for cancer encounters challenges targeting tumor cells directly but delivering miRNA to the tumor stroma offers a straightforward and efficient means of altering the microenvironment, leading to substantial inhibition of tumor growth. AAV-mediated miR-29b delivery to peritoneum via IP route presents a simple, minimally invasive, and promising therapeutic strategy for refractory PM.
  • 上原 朋也, 高橋 和也, 齋藤 心, 大澤 英之, 宮戸 秀世, 金子 勇貴, 加賀谷 丈紘, 金丸 理人, 松本 志郎, 倉科 憲太郎, 細谷 好則, 山口 博紀, 北山 丈二, 佐田 尚宏
    日本臨床外科学会雑誌 85(10) 1469-1469 2024年10月  
  • Shoichi Shinohara, Kosuke Oiwa, Yoshitaka Maeda, Tsuneari Takahashi, Yuji Kaneda, Naohiro Sata, Hironori Yamaguchi, Hiroshi Kawahira
    Cureus 2024年9月20日  
  • 高橋 礼, 大澤 英之, 金子 勇貴, 齋藤 晶, 水津 枝理, 松宮 美沙希, 田村 昂平, 風當 ゆりえ, 園田 洋史, 宮戸 秀世, 山口 博紀, 佐田 尚宏, 北山 丈二, 北山 丈二
    日本癌学会総会記事 83回 P-3082 2024年9月  
  • 井上 亨悦, 相澤 栄俊, 遠藤 裕平, 渡部 文昭, 笹沼 英紀, 野田 弘志, 佐田 尚宏, 力山 敏樹
    臨床消化器内科 39(11) 1427-1431 2024年9月  
    <文献概要>胆嚢軸捻転症および胆嚢出血は,発生頻度が低くまれな病態ではあるが,迅速な対応が求められる.胆嚢軸捻転症は捻転による血流障害により胆嚢壊死をきたし,胆嚢出血は重症化すると胆嚢破裂を引き起こすため,いずれも早急な胆嚢摘出術が必要とされる.臨床症状は胆嚢炎と類似しているため,胆嚢軸捻転症,胆嚢出血を念頭において検査を行わなければ診断に苦慮する.両者とも,対応が遅れた場合には患者の容態が悪化し,予後不良であるため早期診断が重要である.本稿ではこれらの疾患における病態,診断と治療上の注意点について概説する.
  • 井上 亨悦, 相澤 栄俊, 遠藤 裕平, 渡部 文昭, 笹沼 英紀, 野田 弘志, 佐田 尚宏, 力山 敏樹
    臨床消化器内科 39(11) 1427-1431 2024年9月  
    <文献概要>胆嚢軸捻転症および胆嚢出血は,発生頻度が低くまれな病態ではあるが,迅速な対応が求められる.胆嚢軸捻転症は捻転による血流障害により胆嚢壊死をきたし,胆嚢出血は重症化すると胆嚢破裂を引き起こすため,いずれも早急な胆嚢摘出術が必要とされる.臨床症状は胆嚢炎と類似しているため,胆嚢軸捻転症,胆嚢出血を念頭において検査を行わなければ診断に苦慮する.両者とも,対応が遅れた場合には患者の容態が悪化し,予後不良であるため早期診断が重要である.本稿ではこれらの疾患における病態,診断と治療上の注意点について概説する.
  • Kohei Tamura, Natsuka Kimura, Hideyuki Ohzawa, Hideyo Miyato, Naohiro Sata, Takahiro Koyanagi, Yasushi Saga, Yuji Takei, Hiroyuki Fujiwara, Ryozo Nagai, Joji Kitayama, Kenichi Aizawa
    Cancers 16(16) 2841-2841 2024年8月14日  
    Despite advances in systemic chemotherapy, patients with gastric cancer (GC) and peritoneal metastases (PMs) continue to have poor prognoses. Intraperitoneal (IP) administration of Paclitaxel (PTX) combined with systemic chemotherapy shows promise in treating PMs from GC. However, methods of drug administration need to be optimized to maximize efficacy. In this study, we utilized a mouse model with PMs derived from a human GC cell line, administering PTX either IP or intravenously (IV), and Carboplatin (CBDCA) IV 0, 1, and 4 days after PTX administration. The PMs were resected 30 min later, and concentrations of PTX and CBDCA in resected tumors were measured using liquid chromatography–tandem mass spectrometry (LC-MS/MS). Results indicated that PTX concentrations were higher with IP administration than with IV administration, with significant differences observed on days 0 and 1. CBDCA concentrations 4 days post-IP PTX administration were higher than with simultaneous IV PTX administration. These findings suggest that IP PTX administration enhances CBDCA concentration in peritoneal tumors. Therefore, sequential IV administration of anti-cancer drugs appears more effective than simultaneous administration with IP PTX, a strategy that may improve prognoses for patients with PMs.
  • Yuko Homma, Toshiki Mimura, Koji Koinuma, Hisanaga Horie, Naohiro Sata
    Surgery today 54(8) 857-865 2024年8月  
    PURPOSE: Low anterior resection syndrome (LARS) causes devastating symptoms and impairs the quality of life (QOL). This study investigated the incidence and risk factors of LARS and their association with the QOL in patients with lower rectal tumors. METHODS: Patients who underwent anus-preserving surgery for lower rectal tumors between 2014 and 2019 and who had anal defecation between 2020 and 2021 were surveyed. The LARS score measured severity, and the QOL was evaluated using the Japanese version of the Fecal Incontinence Quality-of-Life Scale (JFIQL). The primary endpoint was the incidence of Major LARS, and the secondary endpoints were risk factors and association with the JFIQL. RESULTS: Of 107 eligible patients, 82 (76.6%) completed the LARS survey. The incidence of Major LARS was 48%. Independent risk factors included neoadjuvant chemoradiotherapy (CRT) and a short interval (< 24 months after surgery; odds ratio, 4.6; 95% confidence interval: 1.1-19, both). The LARS score was moderately correlated with the JFIQL generic score (correlation coefficient: - 0.54). The JFIQL scores were significantly worse in the Minor and Major LARS groups than in the No LARS group. CONCLUSIONS: Major LARS was found in 48% of lower rectal tumors, and independent risk factors include neoadjuvant CRT and a short interval. The QOL was significantly impaired in patients with both Minor and Major LARS.
  • 齋藤 心, 山口 博紀, 高橋 和也, 倉科 憲太郎, 佐田 尚宏, 北山 丈二
    臨床消化器内科 39(8) 913-920 2024年7月  
    <文献概要>胃癌治癒切除後の再発部位は腹膜転移が最多であり,その進行により腸閉塞や水腎症,閉塞性黄疸,大量腹水貯留等が生じ,患者のQOLは著しく悪化する.このため,胃癌治療では腹膜播種転移は重要な治療対象と考えられる.腹膜播種を伴う胃癌に対しては,他臓器に転移を有する場合と同様の全身化学療法が実施されてきたが,薬剤の腹膜への移行性が悪いため,一般にその治療効果は乏しいとされる.全身化学療法以外にも,拡大切除,温熱療法,免疫療法などが試されてきたが,未だに腹膜播種病変に対する確立された治療法は存在しない.一方で,近年の抗癌剤治療の進歩に伴いstage IV胃癌であっても奏効症例に対してConversion surgeryが施行され,良好な治療成績が報告されている.本稿では,当施設における腹腔内化学療法の経験を踏まえつつ,胃癌腹膜播種に対する治療戦略を概説する.
  • 高橋 和也, 齋藤 心, 山口 博紀, 加賀谷 丈紘, 金丸 理人, 松本 志郎, 倉科 憲太郎, 細谷 好則, 北山 丈二, 佐田 尚宏
    日本消化器外科学会総会 79回 776-776 2024年7月  
  • 松宮 美沙希, 高橋 和也, 宮戸 秀世, 倉科 憲太郎, 齋藤 心, 大澤 英之, 山口 博紀, 細谷 好則, 佐田 尚宏, 北山 丈二
    日本消化器外科学会総会 79回 910-910 2024年7月  
  • 松本 志郎, 川平 洋, 深田 恭平, 土井 康典, 小林 直, 加賀谷 丈紘, 倉科 憲太郎, 齋藤 心, 細谷 好則, 佐田 尚宏
    日本消化器外科学会総会 79回 2102-2102 2024年7月  
  • 加賀谷 丈紘, 三木 厚, 高橋 和也, 松本 志郎, 倉科 憲太郎, 齋藤 心, 山口 博紀, 細谷 好則, 北山 丈二, 佐田 尚宏
    日本食道学会学術集会プログラム・抄録集 78回 44-44 2024年7月  
  • 齋藤 心, 高木 徹, 山口 博紀, 高橋 和也, 加賀谷 丈紘, 松本 志郎, 倉科 憲太郎, 細谷 好則, 北山 丈二, 佐田 尚宏
    日本食道学会学術集会プログラム・抄録集 78回 228-228 2024年7月  
  • 須藤 慧多, 齋藤 心, 加賀谷 丈紘, 高橋 和也, 松本 志郎, 倉科 憲太郎, 細谷 好則, 山口 博紀, 北山 丈二, 佐田 尚宏
    日本食道学会学術集会プログラム・抄録集 78回 335-335 2024年7月  
  • 安藤 梢, 菅野 敦, 池田 恵理子, 坂口 美織, 佐野 直樹, 田中 朗嗣, 櫻井 祐輔, 横山 健介, 笹沼 英紀, 佐田 尚宏, 福嶋 敬宜, 山本 博徳
    膵臓 39(3) A221-A221 2024年7月  
  • 池田 恵理子, 菅野 敦, 安藤 梢, 坂口 美織, 佐野 直樹, 田中 朗嗣, 櫻井 祐輔, 横山 健介, 笹沼 英紀, 佐田 尚宏, 山本 博徳, 福嶋 敬宜
    膵臓 39(3) A265-A265 2024年7月  
  • 塩澤 徹也, 俵藤 正信, 安田 是和, 笹沼 英紀, 佐田 尚宏
    膵臓 39(3) A338-A338 2024年7月  
  • 下平 健太郎, 笹沼 英紀, 木村 有希, 青木 裕一, 目黒 由行, 田口 昌延, 森嶋 計, 佐久間 康成, 北山 丈二, 佐田 尚宏
    膵臓 39(3) A340-A340 2024年7月  
  • 佐野 直樹, 坂口 美織, 安藤 梢, 池田 恵理子, 菅野 敦, 笹沼 英紀, 佐田 尚宏, 福嶋 敬宜
    膵臓 39(3) A341-A341 2024年7月  
  • 田口 昌延, 笹沼 英紀, 下平 健太郎, 青木 裕一, 目黒 由行, 森嶋 計, 宮戸 秀世, 大澤 英之, 遠藤 和洋, 山口 博紀, 佐久間 康成, 佐田 尚宏
    膵臓 39(3) A346-A346 2024年7月  
  • 渡部 純, 小泉 大, 笹沼 英紀, 佐田 尚宏
    膵臓 39(3) A372-A372 2024年7月  
  • 高橋 礼, 齋藤 晶, 木村 有希, 青木 裕一, 田口 昌延, 森嶋 計, 宮戸 秀世, 大澤 英之, 遠藤 和洋, 笹沼 英紀, 山口 博紀, 佐久間 康成, 川平 洋, 堀江 久永, 細谷 好則, 味村 俊樹, 北山 丈二, 佐田 尚宏
    膵臓 39(3) A373-A373 2024年7月  
  • 森嶋 計, 木村 有希, 青木 裕一, 目黒 由行, 笠原 尚哉, 遠藤 和洋, 笹沼 英紀, 佐久間 康成, 山口 博紀, 北山 丈二, 佐田 尚宏
    膵臓 39(3) A394-A394 2024年7月  
  • 櫻井 祐輔, 菅野 敦, 池田 恵理子, 田中 朗嗣, 安藤 梢, 横山 健介, 小柳 亮太, 田口 昌延, 笹沼 英紀, 佐田 尚宏, 佐野 直樹, 福嶋 敬宜, 山本 博徳
    膵臓 39(3) A399-A399 2024年7月  
  • 笠原 尚哉, 木村 有希, 青木 裕一, 目黒 由行, 田口 昌延, 森嶋 計, 笹沼 英紀, 佐田 尚宏
    膵臓 39(3) A402-A402 2024年7月  
  • 篠田 祐之, 田口 昌延, 下平 健太郎, 木村 有希, 青木 裕一, 目黒 由行, 森嶋 計, 宮戸 秀世, 大澤 英之, 遠藤 和洋, 笹沼 英紀, 山口 博紀, 佐久間 康成, 佐田 尚宏
    膵臓 39(3) A466-A466 2024年7月  
  • 木村 有希, 笹沼 英紀, 青木 裕一, 森嶋 計, 遠藤 和洋, 佐久間 康成, 堀江 久永, 細谷 好則, 北山 丈二, 山口 博紀, 佐田 尚宏
    膵臓 39(3) A488-A488 2024年7月  
  • 利府 数馬, 笹沼 英紀, 木村 有希, 青木 裕一, 田口 昌延, 森嶋 計, 遠藤 和洋, 佐久間 康成, 堀江 久永, 細谷 好則, 山口 博紀, 北山 丈二, 佐田 尚宏
    膵臓 39(3) A489-A489 2024年7月  
  • 青木 裕一, 笹沼 英紀, 木村 有希, 目黒 由行, 田口 昌延, 森嶋 計, 遠藤 和洋, 池田 恵理子, 横山 健介, 菅野 敦, 木原 淳, 福嶋 敬宜, 佐田 尚宏
    膵臓 39(3) A511-A511 2024年7月  
  • Takehiro Kagaya, Atsushi Miki, Jun Watanabe, Rihito Kanamaru, Shiro Matsumoto, Kentaro Kurashina, Shin Saito, Takumi Teratani, Yoshinori Hosoya, Yasunaru Sakuma, Joji Kitayama, Naohiro Sata
    World Journal of Surgery 2024年6月24日  
    Abstract Background Osteopenia reflects frailty and has been shown to be associated with outcomes in cancer patients. This study was undertaken to examine whether osteopenia is an independent prognostic factor in patients with esophageal cancer after resection. Methods A total of 214 patients who underwent surgery for esophageal cancer were analyzed retrospectively. Bone mineral density (BMD) of the 11th thoracic vertebra was measured by computed tomography scan, and patients classified into osteopenia and normal BMD groups with BMD &lt;160 Hounsfield units as the cutoff. Clinicopathological data and prognosis were analyzed. Results The 5‐year survival rate was 55.4% for the osteopenia group and 74.7% for the normal BMD group with a significantly worse prognosis in the osteopenia group (p = 0.0080). In multivariable analysis, osteopenia was a significant independent risk factor associated with overall survival (hazard ratio [HR] 1.90, 95% confidence interval [CI] 1.27–3.34, and p = 0.0151) along with R1/2 resection (HR 3.02, 95% CI 1.71–5.18, and p = 0.0002). Conclusion In patients with esophageal cancer undergoing resection, osteopenia may be a surrogate marker for frailty and an independent predictor of prognosis.
  • 齋藤 心, 高木 徹, 倉科 憲太郎, 風當 ゆりえ, 松本 志郎, 金子 勇貴, 加賀谷 丈紘, 宮戸 秀世, 大澤 英之, 細谷 好則, 北山 丈二, 佐田 尚宏, 山口 博紀
    日本胸部外科学会関東甲信越地方会要旨集 (195回) 27-27 2024年6月  
  • Takahiko Omameuda, Taiichi Wakiya, Yasunaru Sakuma, Yasuharu Onishi, Toshiyuki Yamada, Katsutoshi Takanami, Yukihiro Sanada, Yuta Hirata, Toshio Horiuchi, Naohiro Sata
    Transplantation proceedings 56(5) 1148-1152 2024年6月  
    Alanine aminotransferase (ALT) is an enzyme that catalyzes the transfer of amino groups from alanine to ketoglutaric acid. ALT is an established marker of liver diseases. Occasionally, ALT levels may be abnormally low due to various factors, making accurate assessment difficult. To date, no studies have documented ALT alterations following Living donor liver transplantation (LDLT) in patients with low ALT levels. Here, we present a case of abnormally low ALT levels that were ameliorated by LDLT. A 27-year-old woman underwent LDLT for refractory cholangitis with biliary atresia. The patient's preoperative ALT level was 1 IU/L. Following graft reperfusion, ALT levels increased (peak value, 456 IU/L), primarily attributed to the donor liver. After LDLT, ALT levels consistently surpassed the lower limit. The differential diagnosis of abnormally low ALT levels suggested a genetic mutation as the most probable underlying cause. Even after LDLT, ALT levels in organs other than the transplanted liver would remain abnormally low. Therefore, to prevent underestimating liver damage, the standard ALT range for such cases should be set lower than the typical range.
  • 齋藤 心, 高木 徹, 倉科 憲太郎, 風當 ゆりえ, 松本 志郎, 金子 勇貴, 加賀谷 丈紘, 宮戸 秀世, 大澤 英之, 細谷 好則, 北山 丈二, 佐田 尚宏, 山口 博紀
    日本胸部外科学会関東甲信越地方会要旨集 (195回) 27-27 2024年6月  
  • 津久井 秀則, 堀江 久永, 村橋 賢, 利府 数馬, 本間 祐子, 東條 峰之, 佐田友 藍, 森 和亮, 太白 健一, 太田 学, 伊藤 誉, 井上 賢之, 鯉沼 広治, 山口 博紀, 味村 俊樹, 北山 丈二, 佐田 尚宏
    日本大腸肛門病学会雑誌 77(6) 386-386 2024年6月  
  • Shiro Matsumoto, Hiroshi Kawahira, Kyohei Fukata, Yasunori Doi, Nao Kobayashi, Yoshinori Hosoya, Naohiro Sata
    Scientific Reports 14(1) 2024年5月30日  
    Abstract The advent of Artificial Intelligence (AI)-based object detection technology has made identification of position coordinates of surgical instruments from videos possible. This study aimed to find kinematic differences by surgical skill level. An AI algorithm was developed to identify X and Y coordinates of surgical instrument tips accurately from video. Kinematic analysis including fluctuation analysis was performed on 18 laparoscopic distal gastrectomy videos from three expert and three novice surgeons (3 videos/surgeon, 11.6 h, 1,254,010 frames). Analysis showed the expert surgeon cohort moved more efficiently and regularly, with significantly less operation time and total travel distance. Instrument tip movement did not differ in velocity, acceleration, or jerk between skill levels. The evaluation index of fluctuation β was significantly higher in experts. ROC curve cutoff value at 1.4 determined sensitivity and specificity of 77.8% for experts and novices. Despite the small sample, this study suggests AI-based object detection with fluctuation analysis is promising because skill evaluation can be calculated in real time with potential for peri-operational evaluation.
  • Takashi Ishida, Atsushi Miki, Yasunaru Sakuma, Jun Watanabe, Kazuhiro Endo, Hideki Sasanuma, Takumi Teratani, Joji Kitayama, Naohiro Sata
    Cancers 16(11) 2087-2087 2024年5月30日  
    Background: Osteopenia is a well-known risk factor for survival in patients with hepatocellular carcinoma; however, it is unclear whether osteopenia can apply to both genders and how osteopenia is associated with cancer progression. The aim of this study was to elucidate whether osteopenia predicts reduced survival in regression models in both genders and whether osteopenia is associated with the pathological factors associated with reduced survival. Methods: This study included 188 consecutive patients who underwent hepatectomy. Bone mineral density was assessed using computed tomography (CT) scan images taken within 3 months before surgery. Non-contrast CT scan images at the level of the 11th thoracic vertebra were used. The cutoff value of osteopenia was calculated using a threshold value of 160 Hounsfield units. Overall survival (OS) curves and recurrence-free survival (RFS) were constructed using the Kaplan–Meier method, as was a log-rank test for survival. The hazard ratio and 95% confidence interval for overall survival were calculated using Cox’s proportional hazard model. Results: In the regression analysis, age predicted bone mineral density. The association in females was greater than that in males. The OS and RFS of osteopenia patients were shorter than those for non-osteopenia patients. According to univariate and multivariate analyses, osteopenia was an independent risk factor for OS and RFS. The sole pathological factor associated with osteopenia was microvascular portal vein invasion. Conclusion: Models suggest that osteopenia may predict decreased OS and RFS in patients undergoing resection of hepatocellular carcinoma due to the mechanisms mediated via microvascular portal vein invasion.
  • Yurie Futoh, Hideyo Miyato, Hironori Yamaguchi, Misaki Matsumiya, Rei Takahashi, Yuki Kaneko, Yuki Kimura, Hideyuki Ohzawa, Naohiro Sata, Joji Kitayama, Yoshinori Hosoya
    Scientific Reports 14(1) 2024年4月3日  
    Abstract The vagus nerve is the only pathway for transmitting parasympathetic signals between the brain and thoracoabdominal organs, thereby exhibiting anti-inflammatory functions through the cholinergic anti-inflammatory pathway. Despite often being resected during lymph node dissection in upper gastrointestinal cancer surgery, the impact of vagotomy on postoperative outcomes in gastric cancer patients remains unclear. Sub-diaphragmatic vagotomy was performed on C57BL/6 mice. Three weeks later, syngeneic murine gastric cancer cell line YTN16P was injected into the peritoneal cavity, and the number of peritoneal metastases (PM) on the mesentery and omentum compared with control mice. The phenotypes of immune cells in peritoneal lavage and omental milky spots one day after tumor inoculation were analyzed using flow cytometry and immunohistochemistry. Intraperitoneal transfer of 3 × 105 YTN16P significantly increased the number of metastatic nodules on the mesentery in the vagotomy group compared to the control group. The omental metastasis grade was also significantly higher in the vagotomy group. Phenotypic analysis of immune cells in peritoneal lavage did not reveal significant differences after vagotomy. However, vagotomized mice exhibited a notable increase in milky spot area, with a higher presence of cytokeratin(+) tumor cells, F4/80(+) macrophages, and CD3(+) T cells. Vagus nerve signaling appears to regulate the immune response dynamics within milky spots against disseminated tumor cells and inhibits the development of PM. Preserving the vagus nerve may offer advantages in advanced gastric cancer surgery to reduce peritoneal recurrence.
  • 金子 勇貴, 大澤 英之, 木村 有希, 高橋 礼, 松宮 美沙希, 風當 ゆりえ, 宮戸 英世, 山口 博紀, 細谷 好則, 綿野 亮太, 水上 浩明, 佐田 尚宏, 北山 丈二
    日本外科学会定期学術集会抄録集 124回 SF-4 2024年4月  
  • 高橋 和也, 齋藤 心, 山口 博紀, 大澤 英之, 宮戸 秀世, 金子 勇貴, 加賀谷 丈紘, 金丸 理人, 松本 志郎, 倉科 憲太郎, 細谷 好則, 北山 丈二, 佐田 尚宏
    日本外科学会定期学術集会抄録集 124回 PS-1 2024年4月  
  • 兼田 裕司, 木村 有希, 齋藤 晶, 金子 勇貴, 高橋 礼, 青木 裕一, 目黒 由行, 田口 昌延, 森嶋 計, 笹沼 英紀, 佐久間 康成, 川平 洋, 堀江 久永, 細谷 好則, 味村 俊樹, 山口 博紀, 北山 丈二, 佐田 尚宏
    日本外科学会定期学術集会抄録集 124回 SDGs-7 2024年4月  
  • 太白 健一, 堀江 久永, 太田 学, 村橋 賢, 本間 祐子, 熊谷 祐子, 津久井 秀則, 東條 峰之, 佐田友 藍, 森 和亮, 井上 賢之, 伊藤 誉, 鯉沼 広治, 味村 俊樹, 山口 博紀, 細谷 好則, 北山 丈二, 佐田 尚宏
    日本大腸肛門病学会雑誌 77(4) 268-268 2024年4月  
  • 太田 学, 堀江 久永, 村橋 賢, 利府 数馬, 本間 祐子, 津久井 秀則, 東條 峰之, 佐田友 藍, 森 和亮, 鯉沼 広治, 山口 博紀, 佐久間 康成, 川平 洋, 細谷 好則, 味村 俊樹, 北山 丈二, 佐田 尚宏
    日本外科学会定期学術集会抄録集 124回 SY-5 2024年4月  
  • 太白 健一, 堀江 久永, 太田 学, 宮原 悠三, 本間 祐子, 津久井 秀則, 東條 峰之, 村橋 賢, 森 和亮, 佐田友 藍, 井上 賢之, 伊藤 誉, 鯉沼 広治, 味村 俊樹, 山口 博紀, 細谷 好則, 北山 丈二, 佐田 尚宏
    日本外科学会定期学術集会抄録集 124回 SF-7 2024年4月  
  • Taiichi Wakiya, Yasunaru Sakuma, Yasuharu Onishi, Yukihiro Sanada, Noriki Okada, Yuta Hirata, Toshio Horiuchi, Takahiko Omameuda, Kiichiro Takadera, Naohiro Sata
    Scientific reports 14(1) 6753-6753 2024年3月21日  
    The liver and pancreas work together to recover homeostasis after hepatectomy. This study aimed to investigate the effect of liver resection volume on the pancreas. We collected clinical data from 336 living liver donors. They were categorized into left lateral sectionectomy (LLS), left lobectomy, and right lobectomy (RL) groups. Serum pancreatic enzymes were compared among the groups. Serum amylase values peaked on postoperative day (POD) 1. Though they quickly returned to preoperative levels on POD 3, 46% of cases showed abnormal values on POD 7 in the RL group. Serum lipase levels were highest at POD 7. Lipase values increased 5.7-fold on POD 7 in the RL group and 82% of cases showed abnormal values. The RL group's lipase was twice that of the LLS group. A negative correlation existed between the remnant liver volume and amylase (r = - 0.326)/lipase (r = - 0.367) on POD 7. Furthermore, a significant correlation was observed between POD 7 serum bilirubin and amylase (r = 0.379)/lipase (r = 0.381) levels, indicating cooccurrence with liver and pancreatic strain. Pancreatic strain due to hepatectomy occurs in a resection/remnant liver volume-dependent manner. It would be beneficial to closely monitor pancreatic function in patients undergoing a major hepatectomy.
  • Naoya Yamada, Tadayoshi Karasawa, Junya Ito, Daisuke Yamamuro, Kazushi Morimoto, Toshitaka Nakamura, Takanori Komada, Chintogtokh Baatarjav, Yuma Saimoto, Yuka Jinnouchi, Kazuhisa Watanabe, Kouichi Miura, Naoya Yahagi, Kiyotaka Nakagawa, Takayoshi Matsumura, Ken-Ichi Yamada, Shun Ishibashi, Naohiro Sata, Marcus Conrad, Masafumi Takahashi
    Nature communications 15(1) 2195-2195 2024年3月12日  
    Recent evidence indicates ferroptosis is implicated in the pathophysiology of various liver diseases; however, the organ-specific regulation mechanism is poorly understood. Here, we demonstrate 7-dehydrocholesterol reductase (DHCR7), the terminal enzyme of cholesterol biosynthesis, as a regulator of ferroptosis in hepatocytes. Genetic and pharmacological inhibition (with AY9944) of DHCR7 suppress ferroptosis in human hepatocellular carcinoma Huh-7 cells. DHCR7 inhibition increases its substrate, 7-dehydrocholesterol (7-DHC). Furthermore, exogenous 7-DHC supplementation using hydroxypropyl β-cyclodextrin suppresses ferroptosis. A 7-DHC-derived oxysterol metabolite, 3β,5α-dihydroxycholest-7-en-6-one (DHCEO), is increased by the ferroptosis-inducer RSL-3 in DHCR7-deficient cells, suggesting that the ferroptosis-suppressive effect of DHCR7 inhibition is associated with the oxidation of 7-DHC. Electron spin resonance analysis reveals that 7-DHC functions as a radical trapping agent, thus protecting cells from ferroptosis. We further show that AY9944 inhibits hepatic ischemia-reperfusion injury, and genetic ablation of Dhcr7 prevents acetaminophen-induced acute liver failure in mice. These findings provide new insights into the regulatory mechanism of liver ferroptosis and suggest a potential therapeutic option for ferroptosis-related liver diseases.

MISC

 517

講演・口頭発表等

 966

所属学協会

 10

共同研究・競争的資金等の研究課題

 17